48.96
price down icon0.10%   -0.05
pre-market  Pre-market:  49.30   0.34   +0.69%
loading
Janux Therapeutics Inc stock is traded at $48.96, with a volume of 379.10K. It is down -0.10% in the last 24 hours and down -2.14% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$49.01
Open:
$48.34
24h Volume:
379.10K
Relative Volume:
0.64
Market Cap:
$2.57B
Revenue:
$15.13M
Net Income/Loss:
$-44.05M
P/E Ratio:
-30.04
EPS:
-1.63
Net Cash Flow:
$-47.75M
1W Performance:
-5.83%
1M Performance:
-2.14%
6M Performance:
+2.02%
1Y Performance:
+440.99%
1-Day Range:
Value
$47.61
$49.34
1-Week Range:
Value
$47.04
$52.87
52-Week Range:
Value
$7.79
$65.60

Janux Therapeutics Inc Stock (JANX) Company Profile

Name
Name
Janux Therapeutics Inc
Name
Phone
(858) 751-4493
Name
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Name
Employee
76
Name
Twitter
Name
Next Earnings Date
2024-08-06
Name
Latest SEC Filings
Name
JANX's Discussions on Twitter

Compare JANX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
JANX 48.96 2.57B 15.13M -44.05M -47.75M -1.63
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-06-23 Initiated Wedbush Outperform
Nov-14-22 Initiated William Blair Outperform

Janux Therapeutics Inc Stock (JANX) Latest News

pulisher
Nov 20, 2024

Janux Therapeutics’ Q3 Report: Financials and Progress - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

Stifel Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha

Nov 19, 2024
pulisher
Nov 15, 2024

Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors - Barron's

Nov 15, 2024
pulisher
Nov 13, 2024

Long Term Trading Analysis for (JANX) - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Janux Therapeutics Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 11, 2024

William Blair Predicts Lower Earnings for Janux Therapeutics - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

HC Wainwright Has Negative Outlook of JANX FY2024 Earnings - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

What is HC Wainwright's Forecast for JANX FY2024 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

William Blair Issues Pessimistic Forecast for JANX Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 08, 2024

Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 08, 2024
pulisher
Nov 07, 2024

Janux Therapeutics earnings missed by $0.18, revenue fell short of estimates - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

Janux Therapeutics price target raised to $82 from $62 at BTIG - TipRanks

Nov 07, 2024
pulisher
Nov 06, 2024

Janux Therapeutics Cash Soars to $658M Despite Widening Q3 Losses; Trial Updates Ahead | JANX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Nisa Investment Advisors LLC Has $924,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.3%Here's Why - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

How to Take Advantage of moves in (JANX) - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 01, 2024

Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's

Nov 01, 2024
pulisher
Nov 01, 2024

2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money

Nov 01, 2024
pulisher
Nov 01, 2024

Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Nov 01, 2024
pulisher
Oct 31, 2024

Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St

Oct 28, 2024
pulisher
Oct 27, 2024

Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.

Oct 27, 2024
pulisher
Oct 26, 2024

Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World

Oct 26, 2024
pulisher
Oct 26, 2024

Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World

Oct 26, 2024
pulisher
Oct 24, 2024

UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Janux therapeutics sees significant stock sale by major shareholder Jay Lichter for $178,084 - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials - openPR

Oct 24, 2024
pulisher
Oct 24, 2024

Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics - Barchart

Oct 24, 2024
pulisher
Oct 24, 2024

Janux Therapeutics stock offers upside on T cell engager platform, says UBS - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics - Benzinga

Oct 24, 2024
pulisher
Oct 24, 2024

Janux Therapeutics (NASDAQ:JANX) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

Paradigm Biocapital Advisors LP Acquires Shares in Janux Therape - GuruFocus.com

Oct 23, 2024
pulisher
Oct 23, 2024

RA Capital Management Reduces Stake in Janux Therapeutics - GuruFocus.com

Oct 23, 2024
pulisher
Oct 22, 2024

Insider Buying: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases 1,200,000 Shares of Stock - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Ra Capital Management buys $53.7 million in Janux Therapeutics stock By Investing.com - Investing.com Nigeria

Oct 22, 2024
pulisher
Oct 22, 2024

Ra Capital Management buys $53.7 million in Janux Therapeutics stock - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Vanguard S&P 500 Growth ETF (NYSEARCA:VOOG) Shares Sold by Cwm LLC - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 21, 2024
pulisher
Oct 18, 2024

Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 1,843 Shares - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Janux therapeutics sees $23.8 million in stock sales By Investing.com - Investing.com Australia

Oct 18, 2024
pulisher
Oct 18, 2024

Janux therapeutics sees $23.8 million in stock sales - Investing.com

Oct 18, 2024

Janux Therapeutics Inc Stock (JANX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):